- Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
-
Hoang MD, Jung SH, Lee HJ, Lee YK, Nguyen-Pham TN, Choi NR, Vo MC, Lee SS, Ahn JS, Yang DH, Kim YK, Kim HJ, Lee JJ
- KMID: 2172141
- Chonnam Med J.
- 2015 Apr;51(1):1-7.
- doi: 10.4068/cmj.2015.51.1.1
Although the introduction of stem cell transplantation and novel agents has improved survival, multiple myeloma (MM) is still difficult to cure. Alternative approaches are clearly needed to prolong the survival... -
- CITED
-
- Close
- SHARE
-
- Close
- Cellular immunotherapy in multiple myeloma
-
Vo MC, Lakshmi TJ, Jung SH, Cho D, Park HS, Chu TH, Lee HJ, Kim HJ, Kim SK, Lee JJ
- KMID: 2457017
- Korean J Intern Med.
- 2019 Sep;34(5):954-965.
- doi: 10.3904/kjim.2018.325
In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Sarcoplasmic reticulum Ca²⺠ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells
-
Hong CY, Lee HJ, Choi NR, Jung SH, Vo MC, Hoang MD, Kim HJ, Lee JJ
- KMID: 2361540
- Exp Mol Med.
- 2016 Aug;48(8):e253.
- doi: 10.1038/emm.2016.69
The migration of dendritic cells (DCs) to secondary lymphoid organs depends on chemoattraction through the interaction of the chemokine receptors with chemokines. However, the mechanism of how lymphoid chemokines attract... -
- CITED
-
- Close
- SHARE
-
- Close
